Supplementary materials: Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

<b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–effectiveness of brentuximab vedotin </b><b>for the treatment of cutaneous T-cell </b><b>lymphoma</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table A1</b>: Clinical Inputs.<b>Table A2:</b> Cost Inputs.<b>Table A3: </b>Resource utilization.<b>Table A4:</b> Utility inputs.<b>Aim: </b>To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. <b>Materials &amp; methods:</b> A partitioned survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts.<b> </b><b>Results:</b> Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. <b>Conclusion:</b> BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.

本材料为发表于《比较效果研究杂志（Journal of Comparative Effectiveness Research）》的论文《本妥昔单抗治疗皮肤T细胞淋巴瘤的成本效益分析》的经同行评议补充材料。表A1：临床参数输入；表A2：成本参数输入；表A3：资源利用情况；表A4：效用参数输入。研究目的：评估本妥昔单抗（brentuximab vedotin, BV）对比医师选择方案（甲氨蝶呤或贝沙罗汀）治疗晚期皮肤T细胞淋巴瘤的成本效益。研究材料与方法：从英格兰及威尔士国民保健服务（National Health Service, NHS）的视角构建分区生存模型。模型参数来源于ALCANZA临床试验、英国真实世界数据、已发表文献及临床专家意见。研究结果：在模拟的全生命周期中，本妥昔单抗相较于医师选择方案具有绝对成本效益优势，可额外获得1.58个生命年及1.09个质量调整生命年（quality-adjusted life year, QALY），同时净节省医疗成本119565英镑。当采用30000英镑/质量调整生命年的支付意愿阈值时，净货币收益为152326英镑。敏感性分析及场景分析结果均显示该结论稳健可靠。研究结论：本妥昔单抗是治疗晚期皮肤T细胞淋巴瘤的高成本效益方案。